Evidence map›Paper›PMID 40129585›Full record

ArticleFrontiers in public health2025

Comparison of trend analysis of varicella zoster disease burden between China and the world 1990-2021 and disease burden forecast 2030.

Zhichun Chang, Huale Li, Yanfang Li, Ting Qin, Mingren Hu, Xinjing Yang, Jun Li, Yufeng Xie

Abstract readComparative Study
In one paragraph

Article in Frontiers in public health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Zhichun ChangShenzhen Hospital (Futian) of Guangzhou University of Chinese Medicine, Shenzhen, China.
Huale LiShenzhen Hospital (Futian) of Guangzhou University of Chinese Medicine, Shenzhen, China.
Yanfang LiShenzhen Hospital (Futian) of Guangzhou University of Chinese Medicine, Shenzhen, China.
Ting QinShenzhen Hospital (Futian) of Guangzhou University of Chinese Medicine, Shenzhen, China.
Mingren HuShenzhen Hospital (Futian) of Guangzhou University of Chinese Medicine, Shenzhen, China.
Xinjing YangShenzhen Hospital (Futian) of Guangzhou University of Chinese Medicine, Shenzhen, China.
Jun LiShenzhen Hospital (Futian) of Guangzhou University of Chinese Medicine, Shenzhen, China.
Yufeng XieShenzhen Hospital (Futian) of Guangzhou University of Chinese Medicine, Shenzhen, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objectives: This study aims to analyze temporal trends in the age- and sex-specific burdens of varicella zoster virus (VZV), including incidence, prevalence, mortality, and disability-adjusted life years (DALYs) in China from 1990 to 2021, and to predict the burden of varicella zoster in China for 2030 by comparing the trends with the global burden of the disease. Methods: Data from the Global Burden of Disease database (1990-2021) were used to analyze the characteristics of varicella zoster virus (VZV) burden in China and globally, including trends in incidence, prevalence, mortality, and disability-adjusted life years (DALYs). The average annual percentage change (AAPC) and its corresponding 95% confidence interval (95% CI) were calculated using Joinpoint to assess the VZV burden trends. A comprehensive comparative analysis of the differences in VZV burden between China and the global population was conducted across multiple dimensions, including age, gender, and time period. Additionally, an autoregressive integrated moving average (ARIMA) model was used to predict the VZV trend from 2021 to 2030. Results: Between 1990 and 2021, the age-standardized incidence rate (ASIR) of varicella zoster in China decreased from 1,274.93/100,000 to 1,270.58/100,000, while the global ASIR increased from 1,244.05/100,000 to 1,248.59/100,000. In China, the age-standardized prevalence rate (ASPR) decreased slightly from 72.27/100,000 to 72.03/100,000, whereas the global ASPR rose from 66.67/100,000 to 67.16/100,000. The age-standardized disability-adjusted life year rate (ASDR) in China decreased significantly, from 17.68/100,000 to 4.66/100,000, while the global ASDR decreased from 19.28/100,000 to 12.31/100,000. Similarly, China's age-standardized mortality rate (ASMR) declined significantly, from 0.40/100,000 to 0.05/100,000, while the global ASMR decreased from 0.35/100,000 to 0.19/100,000. Over the same period, the average annual percentage change (AAPC) of ASIR, ASPR, ASMR, and ASDR in China was -0.0056, -0.0131%, -6.84%, and -4.24%, respectively, while the global AAPC for these metrics was 0.0119, 0.0183, -1.97%, and -1.42%, respectively. Additionally, age and gender had a significant impact on the burden of varicella zoster. The trends in ASIR and ASPR were notably influenced by age, while ASMR and ASDR exhibited a significant increasing trend with age. Projections indicate that the ASDR of varicella zoster in China will continue to decrease by 2030, while the ASIR, ASPR, and ASMR are expected to remain stable. Conclusion: Between 1990 and 2021, the incidence, prevalence, mortality, and DALYs of VZV in China demonstrated a declining trend, reflecting a relative reduction in the VZV burden. Women are more susceptible to VZV infection and face a higher risk of mortality than men. In contrast, the global disease burden remains higher than that in China. Projections suggest a slight decrease in the VZV burden in China by 2030. However, due to the country's large and aging population, VZV will continue to pose a significant public health challenge.

Indexed as

Cost of IllnessGlobal Burden of DiseaseHerpes ZosterAdolescentAdultAgedChildChild, PreschoolChinaDisability-Adjusted Life YearsFemaleForecastingGlobal HealthHerpesvirus 3, HumanHumansIncidencedisability-adjusted life yearsincidencemortalityprevalencetrendvaricella zoster disease

Identifiers

PMID40129585
PMCPMC11931152

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.